3 terminated, 1 unknown, 1 withdrawn. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 3, Unknown 1, Withdrawn 1 |
Follow Bellerophon Pulse Technologies: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension INOpulse®, Placebo, Open Label Extension - Pulmonary Fibrosis, Pulmonary Hypertension | Phase 3 | Terminated | Bellerophon Pulse Technologies | 145 | 2020-12-14 | 2023-07-27 |
| A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19 INOpulse, Placebo - COVID-19, Coronavirus | Phase 3 | Terminated | Bellerophon Pulse Technologies | 191 | 2020-07-12 | 2023-02-21 |
| Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric Placebo, iNO - Pulmonary Arterial Hypertension | Phase 3 | Withdrawn | Bellerophon Pulse Technologies | 2018-08-01 | 2023-02-21 | |
| Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo - Pulmonary Arterial Hypertension | Phase 3 | Terminated | Bellerophon Pulse Technologies | 207 | 2016-04-01 | 2023-02-21 |
| Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH Inhaled Nitric Oxide - Pulmonary Arterial Hypertension | Phase 3 | Unknown | Bellerophon Pulse Technologies | 22 | 2016-03-01 | 2023-02-21 |
Pulmonary Arterial Hypertension (3) · COVID-19 (1) · Coronavirus Infections (1) · Hypertension, Pulmonary (1) · Pneumonia (1) · Pulmonary Fibrosis (1) · Severe Acute Respiratory Syndrome (1)
Nitrogen (1)
United States (5) · Canada (4) · Australia (1) · Austria (1) · Belgium (1) · Colombia (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Portugal (1) · Serbia (1)
Ashika Ahmed, MD (4) · Ashika Ahmed (1)